Benefits of Immunotherapy for Cancer: A Complete Guide to Precision Immune-Based Treatment

Benefits of Immunotherapy for Cancer
July 2026 Dr. Abhinav Narwariya 11 Min Read

Benefits of Immunotherapy for Cancer: A Complete 2026 Guide

Immunotherapy is a cancer treatment that trains and strengthens a patient's own immune system to recognize and destroy cancer cells, rather than attacking the tumor directly with drugs or radiation. Its biggest benefit over older treatments is durability — a meaningful share of patients who respond to immunotherapy stay in remission for years after treatment ends, something rarely seen with chemotherapy alone.

Dr. Abhinav Narwariya, Senior Consultant and Unit Head of Medical Oncology at Max Hospital, Shalimar Bagh, Delhi, explains what immunotherapy actually does, which cancers benefit most, what the latest data shows, and how patients in Delhi NCR can find out if they're candidates.

What Is Immunotherapy?

Immunotherapy works by removing the "brakes" cancer cells use to hide from the immune system, or by boosting the immune system's ability to find and attack tumors. The most widely used class — immune checkpoint inhibitors — blocks proteins like PD-1, PD-L1, and CTLA-4 that cancer cells exploit to avoid immune detection. Since the first checkpoint inhibitor was approved in 2011, this class of drugs has become the dominant force in new cancer drug development, with over 150 immunotherapy approvals granted by the U.S. FDA through 2025.

How Immunotherapy Differs from Chemotherapy

Immunotherapy's mechanism — and its potential for durable, treatment-free remission — is what sets it apart from older treatments.

Feature Chemotherapy Immunotherapy
Mechanism Kills fast-dividing cells broadly Activates the immune system to recognize and destroy cancer cells
Testing Required Not usually Often — PD-L1, MSI/MMR, and tumor mutational burden testing
Side Effect Pattern Hair loss, nausea, immune suppression Immune-related inflammation — skin, gut, lungs, or hormone-producing glands
Durability of Response Typically requires ongoing treatment to maintain control Can produce durable remission that continues after treatment stops
Example Drugs Cisplatin, Paclitaxel Pembrolizumab, Nivolumab, Ipilimumab

How Immunotherapy Works: The Biology in Plain Language

Cancer cells are experts at hiding from the immune system. Some tumors hijack natural "checkpoint" proteins that normally stop the immune system from attacking healthy tissue, using them as a disguise. Immunotherapy drugs are designed to block that disguise so T-cells can find and destroy the cancer.

Three checkpoint targets dominate clinical use today:

PD-1 Inhibitors

(e.g., Pembrolizumab, Nivolumab)

Block the PD-1 receptor on T-cells so they can no longer be switched off by tumor cells.

PD-L1 Inhibitors

Target the PD-L1 protein displayed on the surface of tumor cells, preventing it from disarming nearby immune cells.

CTLA-4 Inhibitors

Early T-Cell Activators

Block CTLA-4, a checkpoint that acts earlier in the process, boosting the initial activation of T-cells against the tumor.

Real-World Examples of Immunotherapy in Action

Metastatic Melanoma

Anti-PD-1 and anti-CTLA-4 checkpoint inhibitors are directly credited with more than doubling five-year survival for metastatic melanoma over the past 25 years, and roughly one in three patients achieve a durable objective response to PD-1 antibody therapy.

Non-Small Cell Lung Cancer

Immunotherapy is approved across several lines of lung cancer treatment, with response rates around 19–20%, and PD-L1 testing helps identify patients most likely to benefit.

Kidney and Bladder Cancer

Checkpoint inhibitors have expanded treatment options for advanced kidney cancer, where response rates run around 25%, and for bladder cancer, often used alone or alongside chemotherapy.

Hodgkin Lymphoma

PD-1 inhibitors have become a standard option for relapsed or refractory Hodgkin lymphoma, reflecting immunotherapy's reach beyond solid tumors.

dMMR / MSI-High Tumors

Mismatch-repair-deficient tumors — found in a subset of endometrial, colorectal, and gastric cancers — can respond so strongly to checkpoint blockade alone that researchers are studying whether some patients could avoid surgery or chemotherapy entirely.

The Statistics That Matter in 2026

Immunotherapy continues to reshape cancer outcomes, driving durable responses and expanding treatment options across a growing list of cancer types.

70%

Overall Five-Year Survival

Overall five-year relative survival across all cancers combined has climbed to roughly 70% for patients diagnosed between 2015 and 2021, up from about 49% in the mid-1970s, with immunotherapy cited as one of the primary drivers of recent gains.

35%

Metastatic Melanoma

Five-year survival has more than doubled over the past 25 years, improving from around 16% to roughly 35%, an improvement researchers directly credit to anti-PD-1 and anti-CTLA-4 checkpoint inhibitors.

150+

FDA Immunotherapy Approvals

Over 150 immunotherapy approvals have been granted by the U.S. FDA through 2025, including 13 new approvals in 2025 alone, reflecting an accelerating evidence base.

Combination Regimens and Precision Selection

Combination immunotherapy regimens — checkpoint inhibitors paired with chemotherapy or targeted drugs — are increasingly standard of care in 2025–2026, and have shown two-year survival rates as high as 42% in melanoma retreatment settings, though combination therapy also raises the rate of significant immune-related side effects.

Because response depends heavily on biomarker status, oncologists increasingly rely on PD-L1 expression, tumor mutational burden, and MSI/MMR testing to match the right patient to the right regimen before treatment begins.

"What excites me most about immunotherapy isn't just that it works — it's that when it works, it tends to keep working long after the infusions stop. That durability is fundamentally different from what we saw with chemotherapy-only approaches a generation ago, and it's why biomarker-guided patient selection is now central to how we plan treatment."
Dr. Abhinav Narwariya
Senior Consultant & Unit Head, Medical Oncology
Max Super Speciality Hospital, Shalimar Bagh, Delhi

Who Responds Best to Immunotherapy?

Not every tumor is a good immunotherapy candidate. Response is generally higher in cancers with the following characteristics.

1. High Mutation Burden

Cancers such as melanoma and certain smoking-related lung cancers carry more mutations, which can mean more targets for the immune system to recognize.

2. PD-L1 Positivity

Measured via biopsy, PD-L1 expression helps predict response in lung cancer and several other cancer types.

3. dMMR / MSI-High Status

This genetic signature, found across colorectal, endometrial, and gastric cancers, predicts strong checkpoint-inhibitor response regardless of where the cancer started.

4. Cancer Type & Approval Status

Immunotherapy started with melanoma and lung cancer but now has approved uses across kidney, bladder, and head and neck cancers, Hodgkin lymphoma, and more — increasingly used before and after surgery, not just for advanced disease.

Dr. Narwariya's Practical Framework: 4 Questions to Ask

Dr. Abhinav Narwariya recommends patients and families work through the following four questions with their oncology team to find out if immunotherapy is a fit.

01

What Is My Tumor's Biomarker Profile?

Ask specifically about PD-L1 status, MSI/MMR status, and tumor mutational burden — the strongest available predictors of response.

02

Is Immunotherapy Approved for My Cancer Type and Stage?

Approvals are cancer- and stage-specific, not universal, so confirm your specific diagnosis qualifies before assuming eligibility.

03

Would Combination Therapy Improve My Odds?

Combining immunotherapy with chemotherapy or targeted drugs can raise response rates but also raises toxicity — this is a personalized risk-benefit conversation with your oncology team.

04

What's the Monitoring Plan for Side Effects?

Ask how immune-related symptoms will be tracked and who to contact urgently if something feels wrong during treatment.

Immunotherapy vs. Targeted Therapy vs. Chemotherapy

Although all three treatments are used to fight cancer, they work in different ways and are recommended for different patients depending on the type of cancer and its molecular characteristics.

Question
Immunotherapy
Targeted Therapy
Chemotherapy
How it works Activates the immune system against cancer. Blocks a specific cancer-driving mutation/protein. Kills rapidly dividing cells broadly.
Testing needed first? Often
PD-L1, MSI/MMR, tumor mutation burden. 		Yes
Biomarker-specific testing required. 		No
Best known for Durable, long-term responses in responders. High precision for biomarker-defined tumors. Broad applicability, decades of use.
Typical side effects Immune-related inflammation (skin, gut, glands). Target-specific (skin, blood pressure, liver). Systemic (nausea, hair loss, low counts).

Frequently Asked Questions

Get answers to common questions about cancer immunotherapy, treatment eligibility, and consultation.

Melanoma, certain lung cancers, kidney cancer, bladder cancer, Hodgkin lymphoma, and mismatch-repair-deficient (dMMR) tumors across several organ sites currently show some of the strongest and best-documented immunotherapy responses.

Not universally — it has a different side-effect profile, not necessarily a safer one. Immunotherapy avoids many classic chemotherapy side effects but can cause immune-related inflammation in organs like the skin, gut, lungs, or thyroid, which requires its own monitoring.

Your oncologist will typically test your tumor for biomarkers such as PD-L1 expression, tumor mutational burden, and MSI/MMR status, since these results are the strongest available predictors of response.

For some patients, particularly those who achieve a durable response, immunotherapy can lead to long-term, treatment-free remission. It is not curative for every patient or every cancer type, and outcomes vary based on cancer type, stage, and biomarker status.

Comprehensive immunotherapy planning, biomarker testing coordination, and ongoing monitoring are available through the Medical Oncology department at Max Hospital, Shalimar Bagh, Delhi.

The Bottom Line

Immunotherapy has reshaped cancer treatment over the last decade by offering something chemotherapy rarely could: durable, sometimes long-lasting remission by re-engaging the immune system itself. The benefit isn't universal — response depends heavily on cancer type and biomarker status — but for the patients who qualify and respond, the outcomes can be transformative.

As Dr. Abhinav Narwariya emphasizes, the path to that outcome starts with the right biomarker testing at the right time, not with the drug alone. Patients in Delhi NCR looking for immunotherapy consultation and biomarker-guided treatment planning can access comprehensive medical oncology care at Max Hospital, Shalimar Bagh, including biomarker and molecular testing coordination, immunotherapy and combination-regimen planning, and structured monitoring for treatment side effects.

Medical Disclaimer

This article is for informational purposes and does not replace individualized medical advice. Consult a qualified oncologist to discuss whether immunotherapy is appropriate for your specific diagnosis.

Dr. Abhinav Narwariya

About the Expert

Dr. Abhinav Narwariya

Senior Consultant & Unit Head – Medical Oncology

Dr. Abhinav Narwariya is a Senior Consultant and Unit Head in the Department of Medical Oncology at Max Hospital, Shalimar Bagh, Delhi, specializing in immunotherapy, targeted therapy, and precision oncology.

Book an Appointment
Document